Jennifer Lynn Irani, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Digestive System Surgical Procedures | 5 | 2022 | 576 | 1.420 |
Why?
|
| Anus Neoplasms | 5 | 2024 | 332 | 0.720 |
Why?
|
| Rectal Neoplasms | 7 | 2024 | 1195 | 0.710 |
Why?
|
| Judgment | 1 | 2018 | 281 | 0.540 |
Why?
|
| Enterostomy | 1 | 2013 | 14 | 0.450 |
Why?
|
| Surgical Stomas | 1 | 2013 | 43 | 0.440 |
Why?
|
| Perineum | 4 | 2024 | 211 | 0.420 |
Why?
|
| Appendectomy | 3 | 2019 | 400 | 0.410 |
Why?
|
| General Surgery | 5 | 2015 | 1633 | 0.410 |
Why?
|
| Urethral Stricture | 1 | 2011 | 51 | 0.400 |
Why?
|
| Competency-Based Education | 2 | 2010 | 211 | 0.390 |
Why?
|
| Survival Rate | 24 | 2021 | 12773 | 0.390 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 1509 | 0.380 |
Why?
|
| Androgen Antagonists | 1 | 2019 | 1350 | 0.370 |
Why?
|
| Dilatation | 1 | 2011 | 286 | 0.360 |
Why?
|
| Renal Insufficiency | 2 | 2012 | 802 | 0.350 |
Why?
|
| Neoplasm Staging | 20 | 2021 | 11001 | 0.350 |
Why?
|
| Urethra | 1 | 2011 | 408 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2020 | 9185 | 0.330 |
Why?
|
| Rectum | 3 | 2022 | 903 | 0.330 |
Why?
|
| Testosterone | 1 | 2019 | 2401 | 0.330 |
Why?
|
| Appendiceal Neoplasms | 2 | 2019 | 145 | 0.310 |
Why?
|
| Colorectal Surgery | 2 | 2020 | 129 | 0.300 |
Why?
|
| Hyperthermia, Induced | 2 | 2021 | 401 | 0.290 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2018 | 2229 | 0.290 |
Why?
|
| Treatment Refusal | 2 | 2020 | 416 | 0.290 |
Why?
|
| Internship and Residency | 5 | 2018 | 5774 | 0.280 |
Why?
|
| Operating Rooms | 2 | 2010 | 813 | 0.280 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 350 | 0.270 |
Why?
|
| Self Care | 1 | 2011 | 786 | 0.270 |
Why?
|
| Nephrectomy | 2 | 2011 | 1049 | 0.270 |
Why?
|
| Colorectal Neoplasms | 6 | 2021 | 6754 | 0.260 |
Why?
|
| Colon | 2 | 2022 | 1773 | 0.250 |
Why?
|
| Peritoneal Neoplasms | 2 | 2021 | 663 | 0.250 |
Why?
|
| Clinical Clerkship | 1 | 2010 | 531 | 0.240 |
Why?
|
| Pancreatectomy | 1 | 2008 | 802 | 0.230 |
Why?
|
| Colonic Neoplasms | 3 | 2020 | 2542 | 0.230 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 594 | 0.220 |
Why?
|
| Appendicitis | 2 | 2019 | 644 | 0.210 |
Why?
|
| Graft Survival | 1 | 2012 | 3733 | 0.210 |
Why?
|
| Surgical Flaps | 3 | 2024 | 1634 | 0.200 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2005 | 501 | 0.200 |
Why?
|
| Retrospective Studies | 28 | 2024 | 77098 | 0.200 |
Why?
|
| Kidney Neoplasms | 5 | 2017 | 4229 | 0.200 |
Why?
|
| Databases, Factual | 6 | 2021 | 7716 | 0.190 |
Why?
|
| Medical Staff, Hospital | 1 | 2005 | 603 | 0.190 |
Why?
|
| Follow-Up Studies | 17 | 2019 | 39004 | 0.180 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2018 | 798 | 0.180 |
Why?
|
| BCG Vaccine | 3 | 2018 | 367 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2021 | 4029 | 0.180 |
Why?
|
| Duodenal Neoplasms | 1 | 2020 | 106 | 0.180 |
Why?
|
| France | 2 | 2012 | 517 | 0.180 |
Why?
|
| Prostatitis | 1 | 1999 | 102 | 0.170 |
Why?
|
| Lymph Nodes | 3 | 2020 | 3465 | 0.170 |
Why?
|
| Sigmoidoscopy | 1 | 2019 | 156 | 0.170 |
Why?
|
| Middle Aged | 40 | 2020 | 213127 | 0.160 |
Why?
|
| Carcinoma, Large Cell | 1 | 2019 | 113 | 0.160 |
Why?
|
| Omentum | 1 | 2019 | 170 | 0.160 |
Why?
|
| Goals | 1 | 2023 | 705 | 0.160 |
Why?
|
| Carcinoid Tumor | 1 | 2019 | 235 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2020 | 319 | 0.150 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 4246 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 11472 | 0.150 |
Why?
|
| Abdominal Abscess | 1 | 2018 | 154 | 0.150 |
Why?
|
| Emotional Intelligence | 1 | 2018 | 135 | 0.140 |
Why?
|
| Adenocarcinoma | 7 | 2020 | 6347 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2008 | 1820 | 0.140 |
Why?
|
| Humans | 59 | 2024 | 742088 | 0.140 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 420 | 0.140 |
Why?
|
| Education, Medical, Graduate | 2 | 2005 | 2283 | 0.140 |
Why?
|
| Leiomyosarcoma | 1 | 2020 | 477 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2019 | 3471 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 2951 | 0.140 |
Why?
|
| Male | 42 | 2021 | 349538 | 0.140 |
Why?
|
| Aged | 27 | 2020 | 162944 | 0.140 |
Why?
|
| Microwaves | 1 | 2017 | 191 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 505 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2010 | 4681 | 0.130 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 57683 | 0.130 |
Why?
|
| Mesothelioma | 1 | 2021 | 818 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 325 | 0.130 |
Why?
|
| Endoscopy | 2 | 2022 | 1774 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 3612 | 0.120 |
Why?
|
| Personality | 1 | 2018 | 548 | 0.120 |
Why?
|
| Cystectomy | 2 | 2018 | 682 | 0.120 |
Why?
|
| Prognosis | 12 | 2020 | 29010 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 3151 | 0.120 |
Why?
|
| United States | 11 | 2022 | 69693 | 0.110 |
Why?
|
| Prolapse | 1 | 2013 | 68 | 0.110 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 6891 | 0.110 |
Why?
|
| Antidiarrheals | 1 | 2013 | 45 | 0.110 |
Why?
|
| Abdomen | 1 | 2019 | 1107 | 0.110 |
Why?
|
| Hernia | 1 | 2013 | 71 | 0.110 |
Why?
|
| Ureteral Diseases | 1 | 2012 | 61 | 0.110 |
Why?
|
| Colostomy | 1 | 2013 | 98 | 0.110 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 8621 | 0.110 |
Why?
|
| Dermatitis, Contact | 1 | 2013 | 129 | 0.110 |
Why?
|
| Surgical Wound Infection | 2 | 2019 | 1538 | 0.110 |
Why?
|
| Female | 38 | 2021 | 379592 | 0.110 |
Why?
|
| Ileostomy | 1 | 2013 | 119 | 0.100 |
Why?
|
| Quality of Life | 2 | 2011 | 12730 | 0.100 |
Why?
|
| Treatment Outcome | 12 | 2019 | 62966 | 0.100 |
Why?
|
| Professional Competence | 1 | 2015 | 448 | 0.100 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2013 | 75 | 0.100 |
Why?
|
| Postoperative Complications | 6 | 2024 | 15244 | 0.100 |
Why?
|
| Career Choice | 1 | 2018 | 743 | 0.100 |
Why?
|
| Lymphoma | 1 | 2020 | 1873 | 0.100 |
Why?
|
| Prostatectomy | 2 | 1999 | 1871 | 0.100 |
Why?
|
| Urolithiasis | 1 | 2012 | 131 | 0.100 |
Why?
|
| Surgical Mesh | 1 | 2013 | 256 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5425 | 0.090 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 293 | 0.090 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2011 | 221 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2017 | 1095 | 0.090 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2011 | 230 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2017 | 3123 | 0.090 |
Why?
|
| Adult | 21 | 2019 | 213712 | 0.090 |
Why?
|
| Hospitals, Community | 2 | 2021 | 348 | 0.080 |
Why?
|
| Urinary Incontinence, Stress | 1 | 1991 | 183 | 0.080 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 425 | 0.080 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2012 | 427 | 0.080 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 1208 | 0.080 |
Why?
|
| Incidence | 5 | 2021 | 20928 | 0.080 |
Why?
|
| Necrosis | 1 | 2012 | 1643 | 0.080 |
Why?
|
| Urinary Incontinence | 1 | 2012 | 494 | 0.080 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2008 | 112 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 1994 | 761 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1794 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2020 | 10248 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2020 | 2301 | 0.070 |
Why?
|
| Creatinine | 1 | 2012 | 1916 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 1967 | 0.070 |
Why?
|
| Intestinal Absorption | 1 | 2008 | 420 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2018 | 2121 | 0.070 |
Why?
|
| Mucous Membrane | 1 | 2010 | 670 | 0.070 |
Why?
|
| Suture Techniques | 1 | 1991 | 797 | 0.070 |
Why?
|
| Vagina | 1 | 1991 | 825 | 0.070 |
Why?
|
| Medicaid | 1 | 2019 | 2716 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 4249 | 0.070 |
Why?
|
| Mitomycin | 2 | 2019 | 259 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2011 | 1520 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3070 | 0.060 |
Why?
|
| Sepsis | 1 | 2018 | 2589 | 0.060 |
Why?
|
| Faculty, Medical | 2 | 2010 | 1182 | 0.060 |
Why?
|
| Attitude of Health Personnel | 2 | 2010 | 3839 | 0.060 |
Why?
|
| Risk Factors | 5 | 2019 | 72145 | 0.060 |
Why?
|
| Intestine, Small | 2 | 2020 | 1243 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2017 | 2746 | 0.060 |
Why?
|
| Ileum | 2 | 2020 | 565 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2019 | 692 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2005 | 535 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5133 | 0.050 |
Why?
|
| Time Factors | 3 | 2012 | 40054 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 12242 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 12344 | 0.050 |
Why?
|
| Cell Compartmentation | 1 | 2021 | 402 | 0.050 |
Why?
|
| Melanoma | 1 | 2018 | 5462 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2001 | 247 | 0.040 |
Why?
|
| Urine | 1 | 2001 | 370 | 0.040 |
Why?
|
| Pelvis | 1 | 2024 | 730 | 0.040 |
Why?
|
| Age Factors | 4 | 2020 | 18355 | 0.040 |
Why?
|
| Prostatic Neoplasms | 2 | 1999 | 11039 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 424 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2019 | 199 | 0.040 |
Why?
|
| Acute Disease | 1 | 2008 | 7141 | 0.040 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2019 | 215 | 0.040 |
Why?
|
| Biology | 1 | 2020 | 292 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2021 | 550 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2001 | 600 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 20086 | 0.040 |
Why?
|
| Students, Medical | 1 | 2010 | 1858 | 0.040 |
Why?
|
| Chemokines | 1 | 2021 | 954 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 15530 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2020 | 497 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2021 | 804 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 2623 | 0.040 |
Why?
|
| Administration, Intravesical | 2 | 2010 | 91 | 0.030 |
Why?
|
| Patient Preference | 1 | 2023 | 886 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2021 | 838 | 0.030 |
Why?
|
| Glucose | 1 | 2008 | 4391 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2021 | 1353 | 0.030 |
Why?
|
| Length of Stay | 2 | 2019 | 6294 | 0.030 |
Why?
|
| Immunity | 1 | 2021 | 1011 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 802 | 0.030 |
Why?
|
| Thigh | 1 | 2016 | 247 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 24913 | 0.030 |
Why?
|
| Lithotripsy | 1 | 1995 | 143 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2005 | 2266 | 0.030 |
Why?
|
| Ureteral Calculi | 1 | 1995 | 110 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2019 | 53187 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2015 | 347 | 0.030 |
Why?
|
| Canada | 1 | 2019 | 2061 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 13655 | 0.030 |
Why?
|
| Testicular Hydrocele | 1 | 1993 | 28 | 0.030 |
Why?
|
| Age Distribution | 1 | 2019 | 2900 | 0.030 |
Why?
|
| Propensity Score | 1 | 2020 | 1771 | 0.030 |
Why?
|
| Bleomycin | 1 | 1994 | 499 | 0.030 |
Why?
|
| Seminoma | 1 | 1994 | 136 | 0.030 |
Why?
|
| Sclerosing Solutions | 1 | 1993 | 78 | 0.030 |
Why?
|
| Adolescent | 4 | 2011 | 85649 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2021 | 40450 | 0.030 |
Why?
|
| Etoposide | 1 | 1994 | 637 | 0.030 |
Why?
|
| Vinblastine | 1 | 1994 | 490 | 0.030 |
Why?
|
| Accreditation | 1 | 2015 | 449 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2019 | 1269 | 0.030 |
Why?
|
| Orchiectomy | 1 | 1994 | 466 | 0.030 |
Why?
|
| Minocycline | 1 | 1993 | 163 | 0.030 |
Why?
|
| Monocytes | 1 | 2021 | 2593 | 0.030 |
Why?
|
| Endosonography | 1 | 2015 | 610 | 0.020 |
Why?
|
| Minority Groups | 1 | 2019 | 1215 | 0.020 |
Why?
|
| Kidney Calculi | 1 | 1995 | 465 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 13853 | 0.020 |
Why?
|
| Methods | 1 | 1991 | 1128 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 2721 | 0.020 |
Why?
|
| Colectomy | 1 | 2015 | 681 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2019 | 5062 | 0.020 |
Why?
|
| Neutrophils | 1 | 2021 | 3711 | 0.020 |
Why?
|
| Phlorhizin | 1 | 2008 | 37 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2021 | 3455 | 0.020 |
Why?
|
| Remission Induction | 1 | 1994 | 2384 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1994 | 1248 | 0.020 |
Why?
|
| Cisplatin | 1 | 1994 | 1637 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6534 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2020 | 2493 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2015 | 1365 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7721 | 0.020 |
Why?
|
| Poverty | 1 | 2019 | 2646 | 0.020 |
Why?
|
| Jejunum | 1 | 2008 | 480 | 0.020 |
Why?
|
| Sex Factors | 1 | 2020 | 10392 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3111 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8425 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16665 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2015 | 2680 | 0.020 |
Why?
|
| Contrast Media | 1 | 2017 | 5295 | 0.010 |
Why?
|
| Logistic Models | 1 | 2019 | 13403 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 10163 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2010 | 1484 | 0.010 |
Why?
|
| Calcinosis | 1 | 1991 | 1497 | 0.010 |
Why?
|
| Gravity Sensing | 1 | 2001 | 5 | 0.010 |
Why?
|
| Inflammation | 1 | 2021 | 10578 | 0.010 |
Why?
|
| Work Schedule Tolerance | 1 | 2005 | 565 | 0.010 |
Why?
|
| Urography | 2 | 1991 | 313 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1991 | 2145 | 0.010 |
Why?
|
| Workload | 1 | 2005 | 849 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 3510 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2001 | 1583 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 8300 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 23320 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 2948 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 3339 | 0.010 |
Why?
|
| Angiography | 2 | 1991 | 1636 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 3528 | 0.010 |
Why?
|
| Administration, Intravaginal | 1 | 1993 | 147 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 13029 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7276 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 3915 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1993 | 276 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 3215 | 0.010 |
Why?
|
| Cyproterone Acetate | 1 | 1991 | 6 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 24265 | 0.010 |
Why?
|
| Ultrasonography | 2 | 1995 | 5978 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1997 | 20774 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 12071 | 0.010 |
Why?
|
| Biopsy | 2 | 1991 | 6756 | 0.010 |
Why?
|
| Mastectomy | 1 | 1997 | 1789 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 35342 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1994 | 2968 | 0.000 |
Why?
|
| Disease Progression | 1 | 2001 | 13256 | 0.000 |
Why?
|
| Prostate-Specific Antigen | 1 | 1991 | 2458 | 0.000 |
Why?
|
| Recurrence | 1 | 1993 | 8333 | 0.000 |
Why?
|
| Animals | 1 | 2008 | 168561 | 0.000 |
Why?
|
| Child | 1 | 1995 | 77478 | 0.000 |
Why?
|